Am­gen-part­nered Im­mat­ics bags a $58M round to fund its first clin­i­cal steps on new T-cell tech for can­cer

Back at the be­gin­ning of this year, Am­gen stepped up with a bil­lion-dol­lar smor­gas­bord of mile­stones to en­list Im­mat­ics in a cam­paign to cre­ate some next-gen, T-cell en­gag­ing bis­pecifics for can­cer. And to­day Am­gen came back to the ta­ble to help the biotech put to­geth­er a $58 mil­lion round so it could move its first two in-house drugs through their ini­tial paces in the clin­ic.

Im­mat­ics us­es a plat­form tech dubbed Xpres­i­dent to iden­ti­fy the tar­gets on can­cer cells they want to ze­ro in on. One of their lead­ing pro­grams is for IMA101, ex­pand­ing spe­cif­ic en­doge­nous T cells, which set out in Phase I in Au­gust. Just a few days ago, their close col­lab­o­ra­tors at MD An­der­son launched a Phase I study of IMA201, Im­mat­ics’ TCR can­di­date that reengi­neers T cells to ex­press an ex­oge­nous re­cep­tor — the adop­tive cell ther­a­py ap­proach that has be­come fa­mous in the wake of the first CAR-T ap­proval.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.